Basic and translational research in neonatal pharmacology

Journal of Perinatology

Volumn 26, Issue , 2006, Pages S8-S12

  Ward, R M ^a   Lane, R H ^a   Albertine, K H ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL)CARBOXAMIDO]BENZOIC ACID; ANTIINFECTIVE AGENT; CHLORAMPHENICOL; CYTOCHROME P450 3A4; CYTOCHROME P450 3A7; DEXAMETHASONE; LUNG SURFACTANT; NITRIC OXIDE; PROPYLENE GLYCOL; RETINOL; TOLAZOLINE;

ACCURACY; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC LUNG DISEASE; CLINICAL OBSERVATION; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; COOPERATION; CORRELATION ANALYSIS; DEVELOPMENTAL DISORDER; DRUG DISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EDUCATION PROGRAM; HUMAN; HYPOTHESIS; IN VIVO STUDY; LUNG DYSPLASIA; MEDICAL EDUCATION; MEDICAL RESEARCH; METHODOLOGY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEONATOLOGY; NEUROTOXICITY; NEWBORN; NEWBORN DISEASE; NEWBORN INTENSIVE CARE; NONHUMAN; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; RISK BENEFIT ANALYSIS; SHOCK; WORK ENVIRONMENT;

ANIMALS; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; HUMANS; INFANT, EXTREMELY LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; NEONATOLOGY; PHARMACOLOGY; RESEARCH SUPPORT; RESEARCH SUPPORT AS TOPIC;

EID: 33745636540     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/sj.jp.7211423     Document Type: Article

References (34)

1. Vohr BR, Wright LL, Dusick AM, Mele L, Verter J, Steichen JJ et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993–1994. Pediatrics 2000; 105: 1216.
2. Albertine KH, Jones GP, Starcher BC, Bohnsack JF, Davis PL, Cho SC et al. Chronic lung injury in preterm lambs. Disordered respiratory tract development. Am J Respir Crit Care Med 1999; 159: 945.
3. Ward RM, Beachy JC. Neonatal complications following preterm birth. Br J Obstet Gynec 2003; 110(Suppl 20): 8.
4. O’Shea TM, Klinepeter KL, Goldstein DJ, Jackson BW, Dillard RG. Survival and developmental disability in infants with birth weights of to 800 grams, born between 1979 and 1994. Pediatrics 1997; 100: 982.
5. O’Shea TM, Preisser JS, Klinepeter KL, Dillard RG. Trends in mortality and cerebral palsy in a geographically based cohort of very low birth weight neonates born between 1982 to 1994. Pediatrics 1998; 101: 642.
6. St John EB, Carlo WA. Respiratory distress syndrome in VLBW infants: Changes in management and outcomes observed by the NICHD Neonatal Research Network. Semin Perinatol 2003; 27: 288.
7. Schreiber MD, Gin-Mestan K, Marks JD, Huo D, Lee G, Srisuparp P. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003; 349: 2099.
8. Horbar JD, Stillman AL. Vermont Oxford Network Annual Database Summary for 2000. Vermont Oxford Network: Burlington; 2002.
9. Ward RM. Pharmacologic principles and practicalities. In: Taeusch HW, Ballard RA (eds). Avery’s Diseases of the Newborn. W.B. Saunders: Philadelphia; 1998, pp 404–412.
10. Ward RM. Adverse effects of drugs in the newborn. In: Rudolph CD RA, Hostetter MK, Lister G, Siegel NJ (eds). Rudolph’s Pediatrics. McGraw-Hill: New York; 2003, pp 146–148.
11. Burns LE, Hodgeman JE, Cass AB. Fatal and circulatory collapse in premature infants receiving chloramphenicol. N Engl J Med 1959; 261: 1318.
12. Ward RM, Daniel CH, Kendig JW. Oliguria and tolazoline pharmacokinetics in the newborn. Pediatrics 1986; 77: 307.
13. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver – evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997; 247: 625.
14. Mammel MC, Johnson DE, Green TP, Thompason TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1983; 1: 1356.
15. Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics 1985; 75: 106.
16. Lugo RA, Nahata MC, Menke JA, McClead Jr RE. Pharmacokinetics of dexamethasone in premature neonates. Eur J Clin Pharmacol 1996; 49: 477.
17. Charles B, Schild P, Steer P, Cartwright D, Donovan T. Pharmacokinetics of dexamethasone following single-dose intravenous administration to extremely low birth weight infants. Dev Pharmacol Ther 1993; 20: 205.
18. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S et al. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001; 344: 95.
19. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000; 83: F177.
20. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004; 350: 1304.
21. Romagnoli C, Zecca E, Luciano R, Torrioli G, Tortorolo G. A three year follow up of preterm infants after moderately early treatment with dexamethasone. Arch Dis Child Fetal Neonatal Ed 2002; 87: F55.
22. Canlon B, Erichsen S, Nemlander E, Chen M, Hossain A, Celsi G et al. Alterations in the intrauterine environment by glucocorticoids modifies the developmental programme of the auditory system. Eur J Neurosci 2003; 17: 2035.
23. Ikeda T, Mishima K, Yoshikawa T, Iwasaki K, Fujiwara M, Xia YX et al. Dexamethasone prevents long-lasting learning impairment following neonatal hypoxic-ischemic brain insult in rats. Behav Brain Res 2002; 136: 161.
24. Young TE, Kruyer LS, Marshall DD, Bose CL. Population-based study of chronic lung disease in very low birth weight infants in North Carolina in with comparisons with 1984. The North Carolina Neonatologists Association. Pediatrics 1999; 104: 17.
25. Van Marter LJ, Allred EN, Pagano M, Sanocka U, Parad R, Moore M et al. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics 2000; 105: 1194.
26. Bland RD, Albertine KH, Carlton DP, Kullama L, Davis P, Cho SC et al. Chronic lung injury in preterm lambs: Abnormalities of the pulmonary circulation and lung fluid balance. Pediatr Res 2000; 48: 64.
27. Bland RD, Ling CY, Albertine KH, Carlton DP, MacRitchie AJ, Day RW et al. Pulmonary vascular dysfunction in preterm lambs with chronic lung disease. Am J Physiol Lung Cell Mol Physiol 2003; 285: L76.
28. Thomson MA, Yoder BA, Winter VT, Martin H, Catland D, Siler-Khodr TM et al. Treatment of immature baboons for 28 days with early nasal continuous positive airway pressure. Am J Respir Crit Care Med 2004; 169: 1054.
29. Darlow BA, Graham PJ. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev CD000501.
30. OBrien EA, Zhao L, Dahl MJ, McKnight RA, Reyburn B, Callaway CW et al. NCPAP and vitamin A treatment increase pulmonary TGF-b and SMAD mRNA levels in premature sheep. Pediatr Res 2004; 55: 507A.
31. OBrien EA, Zhao L, McKnight RA, Dahl MJ, Callaway CW, Reyburn B et al. NCPAP and vitamin A treatment increase pulmonary c-myc and c-jun mRNA levels in the premature sheep. Pediatr Res 2004; 55: 507A.
32. Grinder D, Ward RM. Public meeting on the FDA’s proposed regulation requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. J Pediatr Pharm Pract 1997; 2: 331.
33. Ward RM. Children, drugs, and the Food and Drug Administration: Studies of pediatric drugs are beginning to catch up. Pediatr Ann 2001; 30: 189.
34. Leeder JS, Kearns GL. Pharmacogenetics in pediatrics. Implications for practice. Pediatr Clin North Am 1997; 44: 55.